Health Catalyst Stock Price, News & Analysis

Health Catalyst (Nasdaq: HCAT), a leading provider of data and analytics technology for healthcare organizations, has announced its participation in two upcoming investor conferences. The company's leadership team, including CEO Dan Burton, CFO Jason Alger, COO Dan LeSueur, and VP of Investor Relations Jack Knight, will be present at these events:

1. The Wells Fargo Healthcare Conference in Boston, featuring a fireside chat on September 4, 2024, at 1:30pm ET. A webcast link and presentation materials will be available at https://ir.healthcatalyst.com.

2. The Cantor Global Healthcare Conference in New York, including a fireside chat on September 17, 2024, at 8:00am ET.

These conferences provide an opportunity for investors to gain insights into Health Catalyst's operations and future prospects in the healthcare data and analytics sector.

Health Catalyst (Nasdaq: HCAT) has announced an expanded multi-year partnership with Wisconsin Statewide Health Information Network, Inc. (WISHIN). WISHIN will migrate to Health Catalyst's Ninja Universe™ Suite, an end-to-end cloud-native platform designed for Health Information Exchanges (HIEs). This suite includes technologies like Patient Comprehend and HCI Community Interchange, which will enhance WISHIN's ability to aggregate, normalize, and optimize healthcare data in real-time.

The partnership aims to improve interoperability, data security, and healthcare outcomes across Wisconsin. WISHIN CEO Steve Rottmann emphasized the strategic alignment and potential for network expansion, while Health Catalyst CEO Dan Burton expressed commitment to improving health outcomes in Wisconsin through this collaboration.

Health Catalyst (Nasdaq: HCAT) has successfully acquired Lumeon , a digital health company specializing in care orchestration. This strategic move aims to enhance Health Catalyst's core focus on clinical improvement and ambulatory operations, while also supporting its Tech-Enabled Managed Services partnerships. The acquisition combines Lumeon's Care Orchestration technology with Health Catalyst's advanced analytics and AI capabilities, potentially improving healthcare providers' ability to optimize care processes, lower costs, and enhance quality and patient safety.

The deal, funded through a mix of stock and cash, is expected to strengthen Health Catalyst's market position and expand its presence in the United Kingdom and potentially other international markets. Both companies share a mission to enable data-informed healthcare improvement, with the integration aiming to close the loop for data-driven transformation in healthcare organizations.

Health Catalyst (Nasdaq: HCAT) has announced an expanded partnership with Contexture, a nonprofit regional health information exchange organization. The partnership now includes technology and services support for Quality Health Network (QHN), a Contexture affiliate in western Colorado. This expansion follows Contexture and QHN's affiliation in May 2024 to unify services in Colorado and the western slope.

The collaboration will leverage Ninja Universe by Health Catalyst™, a cloud-native platform designed for Health Information Exchanges (HIEs). This platform aggregates, normalizes, and optimizes multi-source healthcare data in real-time, supporting Contexture and QHN's efforts to improve data sharing and patient care in Arizona and Colorado.

Health Catalyst (Nasdaq: HCAT) has expanded its long-term partnership with South Dakota Health Link, enhancing technology and services. This agreement includes migrating to the Ninja Universe, a cloud-native platform for Health Information Exchanges (HIEs), which aggregates and optimizes healthcare data in real-time. South Dakota Health Link serves communities in South Dakota, Wyoming, Minnesota, Iowa, North Dakota, and Nebraska. The collaboration aims to improve healthcare quality, safety, and efficiency by providing healthcare providers, pharmacists, and social workers with real-time data and insights.

Health Catalyst (Nasdaq: HCAT) reported strong Q2 2024 financial results, with total revenue of $75.9 million and Adjusted EBITDA of $7.5 million, both exceeding mid-point guidance. The company saw significant growth in net new Platform Subscription Clients, signing more in H1 2024 than in all of 2023. Key financial metrics include:

- Total revenue: $75.9 million (4% YoY increase)
- Gross profit: $28.8 million (8% YoY increase)
- Gross margin: 38% (up from 36% in Q2 2023)
- Net loss: $13.5 million (59% YoY improvement)
- Adjusted Gross Profit: $37.8 million (4% YoY increase)
- Adjusted EBITDA: $7.5 million (114% YoY increase)

CEO Dan Burton expressed satisfaction with the company's bookings performance and projected a record year for new Platform Subscription Clients.

Health Catalyst (Nasdaq: HCAT), a leading provider of data and analytics technology for healthcare organizations, has announced its plans to release second quarter 2024 operating results on Wednesday, August 7, 2024, after market close. The company will host a conference call at 5 p.m. E.T. on the same day to review the results.

Participants can join the call by dialing 800-267-6316 (U.S.) or 203-518-9783 (international) with the conference ID "HCATQ224". A live audio webcast will be available at https://ir.healthcatalyst.com/, with a replay accessible shortly after the call for approximately 90 days.

Health Catalyst (Nasdaq: HCAT) has secured a $225 million credit facility with Silver Point Finance. The facility includes an initial $125 million term loan and a $100 million delayed draw option. The company will use the funds to refinance existing convertible notes due in 2025 and support its growth strategy.

CEO Dan Burton emphasized the importance of this non-dilutive capital for pursuing organic and inorganic growth opportunities. CFO Jason Alger highlighted the flexibility of the financing structure, allowing Health Catalyst to address near-term debt maturity while focusing on creating shareholder value and maintaining a strong balance sheet.

Health Catalyst (Nasdaq: HCAT) has completed its acquisition of Carevive Systems, a health technology company specializing in oncology. Carevive's platform is used for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and post-treatment care. This acquisition will enhance Health Catalyst's capabilities in oncology care and patient-reported outcomes. Both companies aim to leverage data and analytics to improve patient care and outcomes. The integration promises to deliver innovative solutions to cancer centers and provide researchers with valuable real-world data.